TY  - JOUR
AB  - Since late 2019 the newly emerged pandemic SARS-CoV-2, the causative agent of COVID-19, has hit the world with recurring waves of infections necessitating the global implementation of non-pharmaceutical interventions, including strict social distancing rules, the wearing of masks and the isolation of infected individuals in order to restrict virus transmissions and prevent the breakdown of our healthcare systems. These measures are not only challenging on an economic level but also have a strong impact on social lifestyles. Using traditional and novel technologies, highly efficient vaccines against SARS-CoV-2 were developed and underwent rapid clinical evaluation and approval to accelerate the immunization of the world population, aiming to end the pandemic and return to normality. However, the emergence of virus variants with improved transmission, enhanced fitness and partial immune escape from the first generation of vaccines poses new challenges, which are currently being addressed by scientists and pharmaceutical companies all over the world. In this ongoing pandemic, the evaluation of SARS-CoV-2 vaccines underlies diverse unpredictable dynamics, posed by the first broad application of the mRNA vaccine technology and their compliance, the occurrence of unexpected side effects and the rapid emergence of variations in the viral antigen. However, despite these hurdles, we conclude that the available SARS-CoV-2 vaccines are very safe and efficiently protect from severe COVID-19 and are thereby the most powerful tools to prevent further harm to our healthcare systems, economics and individual lives. This review summarizes the unprecedented pathways of vaccine development and approval during the ongoing SARS-CoV-2 pandemic. We focus on the real-world effectiveness and unexpected positive and negative side effects of the available vaccines and summarize the timeline of the applied adaptations to the recommended vaccination strategies in the light of emerging virus variants. Finally, we highlight upcoming strategies to improve the next generations of SARS-CoV-2 vaccines.
AU  - Günl, Franziska
AU  - Mecate-Zambrano, Angeles
AU  - Rehländer, Selina
AU  - Hinse, Saskia
AU  - Ludwig, Stephan
AU  - Brunotte, Linda
DA  - 2021-09-22
DO  - 10.3390/vaccines9101052
KW  - SARS-CoV-2
KW  - vaccines
KW  - variants
KW  - vaccine safety
KW  - vaccine effectiveness
KW  - adverse effects
KW  - heterologous vaccination
KW  - breakthrough infection
KW  - long Covid
KW  - second generation vaccines
LA  - eng
N1  - Vaccines 9 (2021) 10, 1052, 1-30
N1  - Finanziert durch den Open-Access-Publikationsfonds der Westfälischen Wilhelms-Universität Münster (WWU Münster).
PY  - 2021-09-22
TI  - Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development
UR  - https://nbn-resolving.org/urn:nbn:de:hbz:6-96009453793
Y2  - 2024-11-24T16:17:42
ER  -